{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T23:23:19Z","timestamp":1787354599556,"version":"build-2736575974"},"reference-count":214,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Active cancer by itself but also chemotherapy is associated with an increased risk of cardiovascular disease (CVD) and especially coronary artery disease (CAD) and atrial fibrillation (AF). The frequency of CVD, CAD, and AF varies depending on comorbidities (particularly in older patients), cancer type, and stage, as well as the anticancer therapeutic being taken. Many reports exist for anticancer drugs being associated with CVD, CAD, and AF, but robust data are often lacking. Because of this, each patient needs an individual structured approach concerning thromboembolic and bleeding risk, drug\u2013drug interactions, as well as patient preferences to evaluate the need for anticoagulation therapy and targeting optimal symptom control. Interruption of specific cancer therapy should be avoided to reduce the potential risk of cancer progression. Nevertheless, additional factors like thrombocytopenia and anticoagulation in the elderly and frail patient with cancer cause additional challenges which need to be addressed in daily clinical management. Therefore, the aim of these recommendations is to summarize the available scientific data on antithrombotic therapy (both antiplatelet and anticoagulant therapy) in cancer patients with CVD and in cases of missing data providing guidance for optimal careful decision-making in daily routine.<\/jats:p>","DOI":"10.1055\/a-2337-4025","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T18:56:16Z","timestamp":1721069776000},"page":"250-271","source":"Crossref","is-referenced-by-count":2,"title":["Antithrombotic Therapy in Cancer Patients with Cardiovascular Diseases: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society for Thrombosis and Hemostasis Research (GTH e.V.)"],"prefix":"10.1055","volume":"46","author":[{"given":"Stefani","family":"Parmentier","sequence":"additional","affiliation":[{"name":"Tumorzentrum, St. Claraspital Tumorzentrum, St. Claraspital, Basel, Basel-Stadt, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Henze","sequence":"additional","affiliation":[{"name":"Department of Medicine, Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Rostock, Germany"},{"name":"Department of Internal Medicine II, Hematology, Oncology and Palliative Medicine, Asklepios Hospital Harz, Goslar, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Griesshammer","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Matzdorff","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Asklepios Clinic Uckermark, Schwedt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamam","family":"Bakchoul","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Medical Faculty of T\u00fcbingen, University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Langer","sequence":"additional","affiliation":[{"name":"Center for Oncology, University Cancer Center Hamburg (UCCH), II Medical Clinic and Polyclinic, University Medical Center Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Sonja","family":"Alesci","sequence":"additional","affiliation":[{"name":"IMD Blood Coagulation Center, Hochtaunus\/Frankfurt, Bad Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Duerschmied","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hemostaseology, Angiology and Medical Intensive Care, Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goetz","family":"Thomalla","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno","family":"Riess","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Tumorimmunology, Department of Medical, Campus Charit\u00e9 Mitte, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"issue":"08","key":"ref3","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics-2021 update: a report from the American Heart Association","volume":"143","author":"S S Virani","year":"2021","journal-title":"Circulation"},{"issue":"05","key":"ref4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/HCO.0000000000000878","article-title":"Coronary artery disease in patients with cancer: challenges and opportunities for improvement","volume":"36","author":"M Carrillo-Estrada","year":"2021","journal-title":"Curr Opin Cardiol"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"A A Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"e14841","DOI":"10.1111\/ijcp.14841","article-title":"Trends in cardiovascular mortality of cancer patients in the US over two decades 1999-2019","volume":"75","author":"O Kobo","year":"2021","journal-title":"Int J Clin Pract"},{"issue":"24","key":"ref7","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.3390\/cancers15245885","article-title":"Developing cardio-oncology programs in the new era: beyond ventricular dysfunction due to cancer treatments","volume":"15","author":"A Pons-Riverola","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"07","key":"ref8","first-page":"847","article-title":"The cardio-oncology program: a multidisciplinary approach to the care of cancer patients with cardiovascular disease","volume":"32","author":"S Parent","year":"2016","journal-title":"Can J Cardiol"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ehjqcco\/qcx004","article-title":"Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry","volume":"3","author":"C Melloni","year":"2017","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"A R Lyon","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"08","key":"ref11","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1055\/s-0041-1726298","article-title":"Single, dual, and triple antithrombotic therapy in cancer patients with coronary artery disease: searching for evidence and personalized approaches","volume":"47","author":"C Santoro","year":"2021","journal-title":"Semin Thromb Hemost"},{"issue":"01","key":"ref12","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"R L Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/jamaoncol.2017.3605","article-title":"Prevalence of prior cancer among persons newly diagnosed with cancer: an initial report from the Surveillance, Epidemiology, and End Results Program","volume":"4","author":"C C Murphy","year":"2018","journal-title":"JAMA Oncol"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/eurheartj\/ehaa779","article-title":"Long-term cardiovascular disease mortality among 160 834 5-year survivors of adolescent and young adult cancer: an American population-based cohort study","volume":"42","author":"L Wang","year":"2021","journal-title":"Eur Heart J"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/jnci\/85.12.979","article-title":"Noncancer deaths in white adult cancer patients","volume":"85","author":"B W Brown","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/CLEP.S47385","article-title":"Epidemiology of atrial fibrillation: European perspective","volume":"6","author":"M Zoni-Berisso","year":"2014","journal-title":"Clin Epidemiol"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","article-title":"Insights into onco-cardiology: atrial fibrillation in cancer","volume":"63","author":"D Farmakis","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaccao.2020.09.008","article-title":"Patterns of anticoagulation use in patients with cancer with atrial fibrillation and\/or atrial flutter","volume":"2","author":"M G Fradley","year":"2020","journal-title":"JACC Cardiooncol"},{"issue":"02","key":"ref19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ehjqcco\/qcy040","article-title":"Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF","volume":"5","author":"S T Chen","year":"2019","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.blre.2019.03.005","article-title":"Atrial fibrillation and cancer - an unexplored field in cardiovascular oncology","volume":"35","author":"G Chu","year":"2019","journal-title":"Blood Rev"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/ehjcvp\/pvaa059","article-title":"Cancer treatment and atrial fibrillation: use of pharmacovigilance databases to detect cardiotoxicity","volume":"7","author":"K Keramida","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pcad.2021.04.004","article-title":"Cancer and atrial fibrillation: epidemiology, mechanisms, and anticoagulation treatment","volume":"66","author":"D Menichelli","year":"2021","journal-title":"Prog Cardiovasc Dis"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1186\/s12885-019-6314-9","article-title":"Incidence of atrial fibrillation in different major cancer subtypes: a nationwide population-based 12\u2009year follow up study","volume":"19","author":"C B Jakobsen","year":"2019","journal-title":"BMC Cancer"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaccao.2021.03.006","article-title":"Risk of atrial fibrillation according to cancer type: a nationwide population-based study","volume":"3","author":"J P Yun","year":"2021","journal-title":"JACC Cardiooncol"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10654-017-0231-5","article-title":"Myocardial infarction and future risk of cancer in the general population-the Troms\u00f8 study","volume":"32","author":"L B Rinde","year":"2017","journal-title":"Eur J Epidemiol"},{"issue":"16","key":"ref26","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.jacc.2018.07.077","article-title":"Provider specialty, anticoagulation, and stroke risk in patients with atrial fibrillation and cancer","volume":"72","author":"W T O'Neal","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/s-0030-1255224","article-title":"Cerebrovascular complications in patients with cancer","volume":"30","author":"L R Rogers","year":"2010","journal-title":"Semin Neurol"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/bloodadvances.2017010694","article-title":"Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation","volume":"2","author":"S Shah","year":"2018","journal-title":"Blood Adv"},{"issue":"01","key":"ref29","first-page":"58","article-title":"Net benefit of oral anticoagulants in patients with atrial fibrillation and active cancer: a nationwide cohort study","volume":"22","author":"A Atterman","year":"2020","journal-title":"Europace"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/cncr.33470","article-title":"Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study","volume":"127","author":"D Pastori","year":"2021","journal-title":"Cancer"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2008.01059.x","article-title":"Stroke and cancer: a review","volume":"119","author":"W Grisold","year":"2009","journal-title":"Acta Neurol Scand"},{"issue":"09","key":"ref32","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"A A Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref33","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1097\/HS9.0000000000000750","article-title":"EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer","volume":"6","author":"A Falanga","year":"2022","journal-title":"HemaSphere"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.thromres.2020.06.048","article-title":"Immature platelets: a review of the available evidence","volume":"195","author":"N Benlachgar","year":"2020","journal-title":"Thromb Res"},{"issue":"06","key":"ref35","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/jth.14446","article-title":"Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia","volume":"17","author":"K Adelborg","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ahj.2010.11.001","article-title":"Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial","volume":"161","author":"D A Hakim","year":"2011","journal-title":"Am Heart J"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00277-014-2198-6","article-title":"Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study","volume":"94","author":"I Kopolovic","year":"2015","journal-title":"Ann Hematol"},{"issue":"02","key":"ref38","first-page":"170","article-title":"Occurrence and management of thrombocytopenia in metastatic colorectal cancer patients receiving chemotherapy: secondary analysis of data from prospective clinical trials","volume":"20","author":"K Kilpatrick","year":"2021","journal-title":"Clin Colorectal Cancer"},{"issue":"05","key":"ref39","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/ejh.13595","article-title":"The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies","volume":"106","author":"J L Shaw","year":"2021","journal-title":"Eur J Haematol"},{"issue":"07","key":"ref40","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.3390\/cancers13071532","article-title":"Autoimmune complications in hematologic neoplasms","volume":"13","author":"W Barcellini","year":"2021","journal-title":"Cancers (Basel)"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"790051","DOI":"10.3389\/fimmu.2021.790051","article-title":"Immune thrombocytopenia induced by immune checkpoint inhibitors in lung cancer: case report and literature review","volume":"12","author":"W Xie","year":"2021","journal-title":"Front Immunol"},{"issue":"02","key":"ref42","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/jamaoncol.2021.5680","article-title":"Immune-mediated diseases associated with cancer risks","volume":"8","author":"M M He","year":"2022","journal-title":"JAMA Oncol"},{"issue":"03","key":"ref43","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/jth.13940","article-title":"The association between idiopathic thrombocytopenic purpura and cardiovascular disease: a retrospective cohort study","volume":"16","author":"J S Chandan","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref44","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.amjmed.2017.06.026","article-title":"Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial","volume":"130","author":"C Melloni","year":"2017","journal-title":"Am J Med"},{"issue":"12","key":"ref45","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1016\/j.jtha.2023.09.013","article-title":"Antiplatelet strategies: past, present, and future","volume":"21","author":"L Stanger","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"17","key":"ref46","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1182\/bloodadvances.2022008644","article-title":"The prevalence of thrombocytopenia in patients with acute cancer-associated thrombosis","volume":"7","author":"C Hsu","year":"2023","journal-title":"Blood Adv"},{"issue":"02","key":"ref47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11912-019-0767-5","article-title":"Anticoagulation in cancer patients: a summary of pitfalls to avoid","volume":"21","author":"H K Patel","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1325488","DOI":"10.3389\/fcvm.2023.1325488","article-title":"Antithrombotic strategy in cancer patients comorbid with acute coronary syndrome and atrial fibrillation","volume":"10","author":"T Wang","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"04","key":"ref49","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.acvd.2023.02.005","article-title":"Atrial fibrillation, cancer and anticancer drugs","volume":"116","author":"J Font","year":"2023","journal-title":"Arch Cardiovasc Dis"},{"issue":"12","key":"ref50","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.3390\/cancers13122905","article-title":"Primary thromboprophylaxis in patients with malignancies: daily practice recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology and Oncology (\u00d6GHO)","volume":"13","author":"M Kirschner","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"ref51","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"J Steffel","year":"2021","journal-title":"Europace"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1472-6939-13-22","article-title":"The ethical decisions UK doctors make regarding advanced cancer patients at the end of life \u2013 the perceived (in) appropriateness of anticoagulation for venous thromboembolism: a qualitative study","volume":"13","author":"L Sheard","year":"2012","journal-title":"BMC Med Ethics"},{"issue":"05","key":"ref54","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"N S Key","year":"2020","journal-title":"J Clin Oncol"},{"issue":"05","key":"ref55","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"A Falanga","year":"2023","journal-title":"Ann Oncol"},{"issue":"01","key":"ref56","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1055\/s-0040-1701476","article-title":"Oral anticoagulation in the elderly and frail","volume":"40","author":"R M Bauersachs","year":"2020","journal-title":"Hamostaseologie"},{"issue":"03","key":"ref57","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jaccao.2020.06.001","article-title":"Direct oral anticoagulants in patients with active cancer: a systematic review and meta-analysis","volume":"2","author":"J Sabatino","year":"2020","journal-title":"JACC Cardiooncol"},{"issue":"06","key":"ref58","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(08)70149-9","article-title":"Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis","volume":"9","author":"S I Noble","year":"2008","journal-title":"Lancet Oncol"},{"issue":"01","key":"ref59","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12904-021-00809-z","article-title":"Anticoagulation for patients with mechanical heart valves at the end of life: understanding clinician attitudes and improving decision making","volume":"20","author":"J Raby","year":"2021","journal-title":"BMC Palliat Care"},{"issue":"08","key":"ref60","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/jamainternmed.2021.1819","article-title":"Anticoagulant use for atrial fibrillation among persons with advanced dementia at the end of life","volume":"181","author":"G M Ouellet","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"05","key":"ref61","first-page":"613","article-title":"Deprescribing in palliative cancer care","volume":"12","author":"C Hedman","year":"2022","journal-title":"Life (Basel)"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.thromres.2018.12.028","article-title":"Thromboembolic disease in palliative and end-of-life care: a narrative review","volume":"175","author":"N Chin-Yee","year":"2019","journal-title":"Thromb Res"},{"issue":"11","key":"ref63","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1001\/jamainternmed.2021.4590","article-title":"To deprescribe or not to deprescribe aspirin - a clear indication is the challenge","volume":"181","author":"T Ahuja","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"07","key":"ref64","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/annonc\/mdx172","article-title":"Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study","volume":"28","author":"H Bourgeois","year":"2017","journal-title":"Ann Oncol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(19)32007-0","article-title":"Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study","volume":"395","author":"G R Dagenais","year":"2020","journal-title":"Lancet"},{"issue":"07","key":"ref66","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.117.030816","article-title":"Heart failure stimulates tumor growth by circulating factors","volume":"138","author":"W C Meijers","year":"2018","journal-title":"Circulation"},{"issue":"10","key":"ref67","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s11886-022-01769-3","article-title":"Atrial fibrillation and cancer patients: mechanisms and management","volume":"24","author":"D L Madnick","year":"2022","journal-title":"Curr Cardiol Rep"},{"issue":"01","key":"ref68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","article-title":"Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"13","author":"T Eschenhagen","year":"2011","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"ref69","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/eurheartj\/ehy077","article-title":"International Expert Consensus Document on Takotsubo Syndrome (Part II): diagnostic workup, outcome, and management","volume":"39","author":"J R Ghadri","year":"2018","journal-title":"Eur Heart J"},{"issue":"22","key":"ref70","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/eurheartj\/ehy076","article-title":"International Expert Consensus Document on Takotsubo Syndrome (Part I): clinical characteristics, diagnostic criteria, and pathophysiology","volume":"39","author":"J R Ghadri","year":"2018","journal-title":"Eur Heart J"},{"issue":"32","key":"ref71","doi-asserted-by":"crossref","first-page":"13076","DOI":"10.1073\/pnas.1200419109","article-title":"Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis","volume":"109","author":"M Demers","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"02","key":"ref72","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s00392-020-01719-5","article-title":"Assessment of coronary artery disease during hospitalization for cancer treatment","volume":"110","author":"S M Mrotzek","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.5114\/amsad.2017.72531","article-title":"A unique reason for coronary spasm causing temporary ST elevation myocardial infarction (inferior STEMI) - systemic inflammatory response syndrome after use of pembrolizumab","volume":"2","author":"R Nykl","year":"2017","journal-title":"Arch Med Sci Atheroscler Dis"},{"issue":"04","key":"ref74","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11523-018-0579-9","article-title":"Coronary toxicities of anti-PD-1 and anti-PD-L1 immunotherapies: a case report and review of the literature and international registries","volume":"13","author":"M Ferreira","year":"2018","journal-title":"Target Oncol"},{"issue":"08","key":"ref75","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2018-06-860874","article-title":"Arterial thromboembolic events preceding the diagnosis of cancer in older persons","volume":"133","author":"B B Navi","year":"2019","journal-title":"Blood"},{"issue":"03","key":"ref76","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/jcsm.12694","article-title":"Advanced cancer is also a heart failure syndrome: a hypothesis","volume":"12","author":"M S Anker","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"02","key":"ref77","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/annonc\/mdw604","article-title":"Causes of death among cancer patients","volume":"28","author":"N G Zaorsky","year":"2017","journal-title":"Ann Oncol"},{"issue":"06","key":"ref78","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/jcsm.12633","article-title":"Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know?","volume":"11","author":"A Dolly","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"02","key":"ref79","first-page":"347","article-title":"Cardiac alterations in cancer-induced cachexia in mice","volume":"37","author":"M Tian","year":"2010","journal-title":"Int J Oncol"},{"issue":"14","key":"ref80","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/eurheartj\/eht302","article-title":"Prevention of liver cancer cachexia-induced cardiac wasting and heart failure","volume":"35","author":"J Springer","year":"2014","journal-title":"Eur Heart J"},{"issue":"04","key":"ref81","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/ehf2.12184","article-title":"Cardiac muscle wasting in individuals with cancer cachexia","volume":"4","author":"A Barkhudaryan","year":"2017","journal-title":"ESC Heart Fail"},{"issue":"05","key":"ref82","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/jcsm.12451","article-title":"Rapid atrophy of cardiac left ventricular mass in patients with non-small cell carcinoma of the lung","volume":"10","author":"S MR Kazemi-Bajestani","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"01","key":"ref83","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ejhf.2059","article-title":"Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study","volume":"23","author":"M S Anker","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"ref84","first-page":"1607","article-title":"Management of atrial fibrillation in 2021: an updated comparison of the current CCS\/CHRS, ESC, and AHA\/ACC\/HRS guidelines","volume":"37","author":"C C Cheung","year":"2021","journal-title":"Can J Cardiol"},{"issue":"06","key":"ref85","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/2047487318759858","article-title":"CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer","volume":"25","author":"M D'Souza","year":"2018","journal-title":"Eur J Prev Cardiol"},{"issue":"02","key":"ref86","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"G Y Lip","year":"2010","journal-title":"Chest"},{"issue":"05","key":"ref87","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"G Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"01","key":"ref88","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"74","author":"C T January","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"ref89","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/j.amjcard.2017.08.038","article-title":"Usefulness of CHADS2 and CHA2DS2-VASc scores for stroke prediction in patients with cancer and atrial fibrillation","volume":"120","author":"R Patell","year":"2017","journal-title":"Am J Cardiol"},{"issue":"02","key":"ref90","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijcard.2012.08.036","article-title":"Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients","volume":"165","author":"Y F Hu","year":"2013","journal-title":"Int J Cardiol"},{"issue":"05","key":"ref91","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"R Pisters","year":"2010","journal-title":"Chest"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"757087","DOI":"10.3389\/fcvm.2021.757087","article-title":"Diagnostic accuracy of the HAS-BLED bleeding score in VKA- or DOAC-treated patients with atrial fibrillation: a systematic review and meta-analysis","volume":"8","author":"X Gao","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.amjcard.2021.11.053","article-title":"Incidence and predictors of bleeding in patients with cancer and atrial fibrillation","volume":"167","author":"S Raposeiras Roub\u00edn","year":"2022","journal-title":"Am J Cardiol"},{"issue":"02","key":"ref94","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1538-7836.2011.04572.x","article-title":"Predictors of major bleeding in peri-procedural anticoagulation management","volume":"10","author":"A J Tafur","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"16","key":"ref95","doi-asserted-by":"crossref","first-page":"e008987","DOI":"10.1161\/JAHA.118.008987","article-title":"Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF - TIMI 48 trial","volume":"7","author":"C L Fanola","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"ref96","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"S J Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"ref97","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"R P Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"ref98","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"M R Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"ref99","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"C B Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"02","key":"ref100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11239-020-02304-3","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis","volume":"51","author":"M V Mariani","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"03","key":"ref101","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaccao.2021.06.004","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients with active cancer","volume":"3","author":"S Deitelzweig","year":"2021","journal-title":"JACC Cardiooncol"},{"issue":"06","key":"ref102","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/eurjpc\/zwaa087","article-title":"Anticoagulation for atrial fibrillation in active cancer: what the cardiologists think","volume":"28","author":"D Farmakis","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"09","key":"ref103","first-page":"749","article-title":"Atrial fibrillation in active cancer patients: expert position paper and recommendations","volume":"72","author":"T L\u00f3pez-Fern\u00e1ndez","year":"2019","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"02","key":"ref104","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"A Y Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"07","key":"ref105","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"A YY Lee","year":"2015","journal-title":"JAMA"},{"issue":"17","key":"ref106","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"G Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"07","key":"ref107","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"G E Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"ref108","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"A M Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"02","key":"ref109","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/a-2178-6508","article-title":"Cancer-associated venous thromboembolism-diagnostic and therapeutic considerations: an update based on the revised AWMF S2k guideline","volume":"44","author":"H Riess","year":"2024","journal-title":"Hamostaseologie"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejim.2021.04.002","article-title":"Direct oral anticoagulants versus enoxaparin in patients with atrial fibrillation and active cancer","volume":"89","author":"A Elias","year":"2021","journal-title":"Eur J Intern Med"},{"issue":"08","key":"ref112","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/jth.14478","article-title":"Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: guidance from the SSC of the ISTH","volume":"17","author":"A Delluc","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref113","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1055\/s-0041-1728670","article-title":"Atrial fibrillation, oral anticoagulants, and concomitant active cancer: benefits and risks","volume":"5","author":"A Atterman","year":"2021","journal-title":"TH Open"},{"issue":"24","key":"ref114","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1182\/bloodadvances.2020003238","article-title":"Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases","volume":"4","author":"A Leader","year":"2020","journal-title":"Blood Adv"},{"issue":"16","key":"ref115","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1182\/bloodadvances.2022008086","article-title":"ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis","volume":"6","author":"M Giustozzi","year":"2022","journal-title":"Blood Adv"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.amjcard.2020.12.003","article-title":"Procedural and short-term outcomes of percutaneous left atrial appendage closure in patients with cancer","volume":"141","author":"T Isogai","year":"2021","journal-title":"Am J Cardiol"},{"issue":"23","key":"ref117","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1200\/JCO.2015.65.6603","article-title":"Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer","volume":"34","author":"L W Jones","year":"2016","journal-title":"J Clin Oncol"},{"issue":"03","key":"ref118","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jaccao.2021.07.008","article-title":"Coronary artery disease in young women after radiation therapy for breast cancer: the WECARE study","volume":"3","author":"L E Carlson","year":"2021","journal-title":"JACC Cardiooncol"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.radonc.2021.08.012","article-title":"Radiation therapy related cardiac disease risk in childhood cancer survivors: updated dosimetry analysis from the Childhood Cancer Survivor Study","volume":"163","author":"S Shrestha","year":"2021","journal-title":"Radiother Oncol"},{"issue":"13","key":"ref120","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1200\/JCO.2016.70.0229","article-title":"Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy","volume":"35","author":"K Wang","year":"2017","journal-title":"J Clin Oncol"},{"issue":"23","key":"ref121","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/eurheartj\/ehz851","article-title":"Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA","volume":"41","author":"A Bharadwaj","year":"2020","journal-title":"Eur Heart J"},{"issue":"07","key":"ref122","first-page":"631","article-title":"Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy","volume":"7","author":"M Iannaccone","year":"2018","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijcard.2018.10.008","article-title":"Acute coronary syndromes in patients with active hematologic malignancies - incidence, management, and outcomes","volume":"275","author":"J Y Park","year":"2019","journal-title":"Int J Cardiol"},{"issue":"07","key":"ref124","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/clc.22007","article-title":"Treatment and outcomes of acute coronary syndrome in the cancer population","volume":"35","author":"S W Yusuf","year":"2012","journal-title":"Clin Cardiol"},{"issue":"22","key":"ref125","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/eurheartj\/ehy769","article-title":"Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States","volume":"40","author":"J E Potts","year":"2019","journal-title":"Eur Heart J"},{"issue":"02","key":"ref126","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaccao.2019.11.001","article-title":"Ischemia and bleeding in cancer patients undergoing percutaneous coronary intervention","volume":"1","author":"Y Ueki","year":"2019","journal-title":"JACC Cardiooncol"},{"issue":"08","key":"ref127","first-page":"829","article-title":"Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis","volume":"10","author":"M O Mohamed","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"03","key":"ref128","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/ejcts\/ezaa114","article-title":"Coronary artery bypass grafting in patients with concomitant solid tumours: early and long-term results","volume":"58","author":"A Garatti","year":"2020","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"100119","DOI":"10.1016\/j.ajpc.2020.100119","article-title":"Association between coronary artery calcium and cardiovascular disease as a supporting cause in cancer: The CAC consortium","volume":"4","author":"F M Wang","year":"2020","journal-title":"Am J Prev Cardiol"},{"issue":"41","key":"ref130","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"A R Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"14","key":"ref131","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"F I Mulder","year":"2021","journal-title":"Blood"},{"issue":"01","key":"ref132","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/cancers12010075","article-title":"A case-control analysis of the impact of venous thromboembolic disease on quality of life of patients with cancer: Quality of Life in Cancer (Qca) Study","volume":"12","author":"L Marin-Barrera","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"07","key":"ref133","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/cncr.25714","article-title":"Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis","volume":"117","author":"G H Lyman","year":"2011","journal-title":"Cancer"},{"issue":"10","key":"ref134","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"P Prandoni","year":"2002","journal-title":"Blood"},{"issue":"02","key":"ref135","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer-associated venous thromboembolism: burden, mechanisms, and management","volume":"117","author":"C Ay","year":"2017","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref136","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamacardio.2018.4537","article-title":"Cardiovascular risk factors associated with venous thromboembolism","volume":"4","author":"J Gregson","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"07","key":"ref137","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/s41416-019-0721-1","article-title":"Cancer as a disease of old age: changing mutational and microenvironmental landscapes","volume":"122","author":"E Laconi","year":"2020","journal-title":"Br J Cancer"},{"issue":"05","key":"ref138","first-page":"1049","article-title":"Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy","volume":"104","author":"M Di Nisio","year":"2010","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref139","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"S V Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"03","key":"ref140","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.thromres.2015.07.011","article-title":"Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants","volume":"136","author":"F Posch","year":"2015","journal-title":"Thromb Res"},{"issue":"06","key":"ref141","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.thromres.2014.09.039","article-title":"Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis","volume":"134","author":"M Carrier","year":"2014","journal-title":"Thromb Res"},{"issue":"01","key":"ref142","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/jth.13563","article-title":"Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice","volume":"15","author":"S J van der Wall","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref143","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/jth.15280","article-title":"An epidemic of redundant meta-analyses","volume":"19","author":"C Chapelle","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref144","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial","volume":"18","author":"R D McBane II","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref145","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"B Planquette","year":"2022","journal-title":"Chest"},{"issue":"22","key":"ref146","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"D Schrag","year":"2023","journal-title":"JAMA"},{"issue":"04","key":"ref147","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/rth2.12359","article-title":"Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials","volume":"4","author":"F Moik","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"10","key":"ref148","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"D Farge","year":"2019","journal-title":"Lancet Oncol"},{"issue":"04","key":"ref150","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"G H Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"06","key":"ref151","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","article-title":"Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST Guideline and Expert Panel Report","volume":"160","author":"S M Stevens","year":"2021","journal-title":"Chest"},{"issue":"06","key":"ref152","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.3390\/curroncol28060453","article-title":"Treatment algorithm in cancer-associated thrombosis: updated Canadian Expert Consensus","volume":"28","author":"M Carrier","year":"2021","journal-title":"Curr Oncol"},{"issue":"02","key":"ref153","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/ejh.13338","article-title":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial","volume":"104","author":"R D McBane II","year":"2020","journal-title":"Eur J Haematol"},{"issue":"04","key":"ref154","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1055\/a-1647-9896","article-title":"Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study","volume":"122","author":"I Mahe","year":"2022","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref156","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","article-title":"2020 ACC Expert Consensus Decision Pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"77","author":"D J Kumbhani","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"ref157","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3324\/haematol.2015.127126","article-title":"Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology","volume":"100","author":"S Noble","year":"2015","journal-title":"Haematologica"},{"issue":"10","key":"ref158","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3324\/haematol.12948","article-title":"Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study","volume":"93","author":"M Hunault-Berger","year":"2008","journal-title":"Haematologica"},{"key":"ref159","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/asheducation-2007.1.151","article-title":"Double hazard of thrombophilia and bleeding in leukemia","author":"H C Kwaan","year":"2007","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"05","key":"ref160","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies","volume":"15","author":"J J Shatzel","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref161","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/hon.2503","article-title":"Practical management of ibrutinib in the real life: focus on atrial fibrillation and bleeding","volume":"36","author":"G Boriani","year":"2018","journal-title":"Hematol Oncol"},{"issue":"15","key":"ref162","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia","volume":"386","author":"D J Kuter","year":"2022","journal-title":"N Engl J Med"},{"key":"ref163","doi-asserted-by":"crossref","first-page":"1076029620936325","DOI":"10.1177\/1076029620936325","article-title":"Drug-drug interactions of 257 antineoplastic and supportive care agents with 7 anticoagulants: a comprehensive review of interactions and mechanisms","volume":"26","author":"E JF Peixoto de Miranda","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref164","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.critrevonc.2018.09.015","article-title":"Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: potential for drug-drug interactions","volume":"132","author":"H Riess","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"01","key":"ref165","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1634\/theoncologist.2013-0239","article-title":"New oral anticoagulants and the cancer patient","volume":"19","author":"N J Short","year":"2014","journal-title":"Oncologist"},{"issue":"06","key":"ref166","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/bcp.13092","article-title":"Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine","volume":"82","author":"D A Parasrampuria","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"08","key":"ref167","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"A J Claxton","year":"2001","journal-title":"Clin Ther"},{"issue":"10","key":"ref168","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1111\/jth.14976","article-title":"Von Willebrand factor and cancer; metastasis and coagulopathies","volume":"18","author":"S Patmore","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref169","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/bjh.18322","article-title":"Practical management of the haemorrhagic complications of myeloproliferative neoplasms","volume":"199","author":"E Jones","year":"2022","journal-title":"Br J Haematol"},{"key":"ref170","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.clinthera.2009.11.020","article-title":"Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007","volume":"31","author":"Y Wu","year":"2009","journal-title":"Clin Ther"},{"issue":"12","key":"ref171","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2165\/11594310-000000000-00000","article-title":"Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital-based cohort study","volume":"34","author":"M J Ten Berg","year":"2011","journal-title":"Drug Saf"},{"issue":"01","key":"ref172","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/hematology.2019000369","article-title":"Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy","volume":"2019","author":"H Al-Samkari","year":"2019","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"06","key":"ref173","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"B T Samuelson Bannow","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref174","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/rth2.12111","article-title":"Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review","volume":"2","author":"B R Samuelson Bannow","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"S 01","key":"ref175","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/S0049-3848(20)30400-X","article-title":"Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia","volume":"191","author":"A Leader","year":"2020","journal-title":"Thromb Res"},{"issue":"04","key":"ref176","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s11239-018-1792-1","article-title":"Effectiveness and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with thrombocytopenia","volume":"47","author":"C L Wang","year":"2019","journal-title":"J Thromb Thrombolysis"},{"issue":"03","key":"ref177","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/FJC.0000000000000607","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and thrombocytopenia","volume":"72","author":"A Janion-Sadowska","year":"2018","journal-title":"J Cardiovasc Pharmacol"},{"issue":"01","key":"ref178","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/clc.23287","article-title":"Impact of immune thrombocytopenic purpura on clinical outcomes in patients with acute myocardial infarction","volume":"43","author":"O Chehab","year":"2020","journal-title":"Clin Cardiol"},{"issue":"S 01","key":"ref179","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1053\/j.seminhematol.2013.03.020","article-title":"Immune thrombocytopenia patients requiring anticoagulation \u2013 maneuvering between Scylla and Charybdis","volume":"50","author":"A Matzdorff","year":"2013","journal-title":"Semin Hematol"},{"issue":"47","key":"ref180","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1093\/eurheartj\/ehx531","article-title":"The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum","volume":"38","author":"C P McCarthy","year":"2017","journal-title":"Eur Heart J"},{"issue":"01","key":"ref181","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11239-018-1649-7","article-title":"Management of antithrombotic therapy in adults with immune thrombocytopenia (ITP): a survey of ITP specialists and general hematologist-oncologists","volume":"46","author":"A M Pishko","year":"2018","journal-title":"J Thromb Thrombolysis"},{"key":"ref182","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.thromres.2016.03.011","article-title":"Variability in management of hematologic malignancy patients with venous thromboembolism and chemotherapy-induced thrombocytopenia","volume":"141","author":"B T Samuelson","year":"2016","journal-title":"Thromb Res"},{"issue":"09","key":"ref183","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/jth.12338","article-title":"Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH","volume":"11","author":"M Carrier","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref184","first-page":"210","article-title":"Outcomes of hospitalized patients with myocardial infarction and immune thrombocytopenic purpura: a cross sectional study over 15 years","volume":"10","author":"S J Patel","year":"2020","journal-title":"Am J Blood Res"},{"issue":"04","key":"ref185","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4070\/kcj.2014.44.4.264","article-title":"Revascularization for patients with idiopathic thrombocytopenic purpura and coronary artery disease","volume":"44","author":"C H Lee","year":"2014","journal-title":"Korean Circ J"},{"issue":"02","key":"ref186","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1510\/icvts.2011.271296","article-title":"Idiopathic thrombocytopenic purpura and coronary artery disease: comparison between coronary artery bypass grafting and percutaneous coronary intervention","volume":"13","author":"A Russo","year":"2011","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"06","key":"ref187","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa460","article-title":"Management of acute myocardial infarction in a patient with idiopathic thrombocytopenic purpura, the value of optical coherence tomography: a case report","volume":"4","author":"K Al-Lawati","year":"2020","journal-title":"Eur Heart J Case Rep"},{"issue":"01","key":"ref188","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1067\/mhj.2000.108239","article-title":"Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators","volume":"140","author":"D L Bhatt","year":"2000","journal-title":"Am Heart J"},{"issue":"24","key":"ref189","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"H Watanabe","year":"2019","journal-title":"JAMA"},{"issue":"01","key":"ref190","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/trf.15069","article-title":"Platelet transfusion practices in immune thrombocytopenia related hospitalizations","volume":"59","author":"R Goel","year":"2019","journal-title":"Transfusion"},{"issue":"18","key":"ref191","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/j.jcin.2018.05.033","article-title":"Impact of chronic thrombocytopenia on in-hospital outcomes after percutaneous coronary intervention","volume":"11","author":"K Ayoub","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"02","key":"ref192","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1253\/jcj.63.133","article-title":"Primary percutaneous transluminal coronary angioplasty performed for acute myocardial infarction in a patient with idiopathic thrombocytopenic purpura","volume":"63","author":"T Fuchi","year":"1999","journal-title":"Jpn Circ J"},{"issue":"08","key":"ref193","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.mayocp.2016.05.008","article-title":"Effect of preprocedural thrombocytopenia on prognosis after percutaneous coronary intervention","volume":"91","author":"C E Raphael","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"02","key":"ref194","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/2013.jamainternmed.1001","article-title":"Association of blood transfusion with increased mortality in myocardial infarction: a meta-analysis and diversity-adjusted study sequential analysis","volume":"173","author":"S Chatterjee","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"23","key":"ref195","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"C Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"20","key":"ref196","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"D A Arber","year":"2016","journal-title":"Blood"},{"issue":"04","key":"ref197","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors","volume":"115","author":"T Barbui","year":"2010","journal-title":"Blood"},{"issue":"26","key":"ref198","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"T Barbui","year":"2012","journal-title":"Blood"},{"issue":"22","key":"ref199","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"A Carobbio","year":"2011","journal-title":"Blood"},{"issue":"19","key":"ref200","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","article-title":"In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology","volume":"124","author":"T Barbui","year":"2014","journal-title":"Blood"},{"issue":"10","key":"ref201","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood-2012-10-429134","article-title":"Platelet activation and inhibition in polycythemia vera and essential thrombocythemia","volume":"121","author":"C Patrono","year":"2013","journal-title":"Blood"},{"issue":"13","key":"ref202","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"T Barbui","year":"2013","journal-title":"Blood"},{"issue":"05","key":"ref203","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"T Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"02","key":"ref204","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"R Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"03","key":"ref205","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-018-0048-9","article-title":"Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms","volume":"8","author":"V De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"issue":"06","key":"ref206","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00277-015-2330-2","article-title":"Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia","volume":"94","author":"J C Hern\u00e1ndez-Boluda","year":"2015","journal-title":"Ann Hematol"},{"issue":"04","key":"ref207","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s12185-017-2282-5","article-title":"Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms","volume":"106","author":"J C Ianotto","year":"2017","journal-title":"Int J Hematol"},{"issue":"S 01","key":"ref208","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1182\/blood-2019-127600","article-title":"Direct oral anticoagulants for prevention of recurrent thrombosis in myeloproliferative neoplasms","volume":"134","author":"K Fedorov","year":"2019","journal-title":"Blood"},{"issue":"08","key":"ref209","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-020-04350-6","article-title":"Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE\/VTE) in myeloproliferative neoplasms","volume":"100","author":"K Huenerbein","year":"2021","journal-title":"Ann Hematol"},{"issue":"10","key":"ref210","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1038\/s41375-021-01279-1","article-title":"Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients","volume":"35","author":"T Barbui","year":"2021","journal-title":"Leukemia"},{"issue":"05","key":"ref211","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3324\/haematol.2021.279032","article-title":"Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study","volume":"107","author":"J I Zwicker","year":"2022","journal-title":"Haematologica"},{"issue":"12","key":"ref212","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00277-014-2224-8","article-title":"Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (\u00d6GHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.)","volume":"93","author":"S Kreher","year":"2014","journal-title":"Ann Hematol"},{"issue":"05","key":"ref213","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00277-016-2621-2","article-title":"Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)","volume":"95","author":"I Appelmann","year":"2016","journal-title":"Ann Hematol"},{"issue":"07","key":"ref214","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.3324\/haematol.2019.227876","article-title":"Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study","volume":"105","author":"F Paciullo","year":"2020","journal-title":"Haematologica"},{"issue":"09","key":"ref215","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","article-title":"ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders","volume":"8","author":"F Rodeghiero","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref216","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/jth.14683","article-title":"Validation of the ISTH\/SSC bleeding assessment tool for inherited platelet disorders: a communication from the Platelet Physiology SSC","volume":"18","author":"P Gresele","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"25","key":"ref217","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1182\/blood-2018-08-868406","article-title":"Managing antithrombotic therapy in immune thrombocytopenia: development of the TH2 risk assessment score","volume":"132","author":"A K Balitsky","year":"2018","journal-title":"Blood"},{"issue":"09","key":"ref218","first-page":"706","article-title":"Superior safety of direct oral anticoagulants compared to warfarin in patients with atrial fibrillation and underlying cancer: a national Veterans Affairs database study","volume":"16","author":"A C Sawant","year":"2019","journal-title":"J Geriatr Cardiol"},{"issue":"06","key":"ref219","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/eurjpc\/zwaa054","article-title":"Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management","volume":"28","author":"G Boriani","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"ref220","first-page":"215","article-title":"Patient education program at the forefront of cancer-associated thrombosis care","volume":"46","author":"M Sebuhyan","year":"2021","journal-title":"J Med Vasc"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2337-4025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T22:31:05Z","timestamp":1787351465000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2337-4025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":214,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2026,8,21]]},"published-print":{"date-parts":[[2026,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2337-4025","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]}}}